Publication — IRIC

Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.

Distinguishing lung adenocarcinoma (ADC) from squamous cell carcinoma (SCC) has a tremendous therapeutic implication. Sometimes, the commonly used immunohistochemistry (IHC) markers fail to discriminate between them, urging for the identification of new diagnostic biomarkers.

Publication date
August 1, 2018
Principal Investigators
El-Khoury V, Béland M, Schritz A, Kim SY, Nazarov PV, Gaboury L, Sertamo K, Bernardin F, Batutu R, Antunes L, Bennett CW, Faÿs F, Berchem G, Kim YJ
PubMed reference
Br. J. Cancer 2018;119(5):580-590
PubMed ID
Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, 1 A-B Rue Thomas Edison, L-1445, Strassen, Luxembourg.